Answers are grounded in this paper and cite their sources.
Gene therapy (GT) is an emerging strategy for the treatment of genetic cardiomyopathies (CMs), with many programs currently in development.1 As these therapies advance through clinical trials and toward clinical implementation, understanding the perspectives of patients and families will be important for guiding education, shared decision-making, and clinical trial participation, given the complex safety, ethical, and implementation considerations.1-3 Preliminary studies suggest that individuals affected by CM are generally supportive of GT, yet data remain limited.
No takes yet. Share an insight, caveat, or question.
Silver et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: